共 146 条
[1]
Alessandro R(2021)Risk of selected gastrointestinal toxicities in metastatic renal cell carcinoma patients treated with immuno-SM-TKI combinations: a meta-analysis Expert Rev Gastroenterol Hepatol 15 1225-1232
[2]
Veronica M(2016)Endoscopy in patients with diarrhea during treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors: Is the cause in the mucosa? Acta Oncol 55 444-448
[3]
Matteo S(2012)Systemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and management Ann Gastroenterol 25 106-118
[4]
Francesco M(2018)Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies Cancer Manag Res 347 472-480
[5]
Boers-Sonderen MJ(2002)Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 160 1384-1393
[6]
Mulder SF(2021)AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review Gastroenterology 31 3639-3646
[7]
Nagtegaal ID(2013)Cabozantinib in progressive medullary thyroid cancer J Clin Oncol 211 45-56
[8]
Boussios S(2018)Regorafenib Recent Resul Cancer Res 27 83-87
[9]
Pentheroudakis G(2008)Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma Invest New Drugs 381 303-312
[10]
Katsanos K(2012)Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial Lancet 10 470-481